Management and decision making in HPV driven OPC

• HN 05-01 • Molecular and immune markers that have an impact on treatment > C. Carole FAKHRY • HN 05-02 • Treatment of HPV OPC systemic treatment > A. Amanda PSYRRI • HN 05-03 • Potential advantages of robotic surgery > C. Carole FAKHRY • HN 05-04 • The value of radiotherapy > H. Harry QUON • HN 05-05 • The use of different biomarkers for predicting clinical outcome in tonsillar and base of tongue cancer See abstract > T. Tina DALIANIS • HN 05-07 • Risk groups for recurrences, metastasis and survival > S. Sara PAI • HN 05-08 • Treatment for recurrent/metastatic HPV+ OPC tumors > C. Carole FAKHRY • HN 05-09 • Quality of life following HPV driven OPC See abstract > G. Gypsyamber D'souza